BROOKLYN, N.Y.– Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders and monogenic diseases, today announced that management will host a conference call on Tuesday, May 25, 2021 at 4:30 p.m. Eastern Time (ET).
Participants are asked to pre-register for the call through the following link: http://www.directeventreg.com/registration/event/6819283. Please note that registered participants will receive their dial in number upon registration and will dial directly into the call.
The conference call will also be available through a live webcast found here.
The Company invites participants to pre-submit questions to firstname.lastname@example.org until 5:00 p.m. Eastern Time (ET) on May 20, 2021 (live questions will not be accepted during the call). Please use the subject line, “BTX Call Questions” for this correspondence. The Company will do its best to address all pre-submitted questions at the conclusion of prepared remarks.
About Brooklyn ImmunoTherapeutics
Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also expoloring opportunities to advance oncology, blood disorders, and monogenic disease therapies using leading edge gene editing/cell therapy technology through the newly acquired license from Factor Bioscience Limited and Eterna Therapeutics Limited.
Brooklyn’s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.